Draft octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg or 30 mg product-specific bioequivalence guidance

  • Email
  • Help

Document details

Download document Draft octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg or 30 mg product-specific bioequivalence guidance
Reference number EMA/CHMP/291571/2018
Status draft: consultation open
First published 2018-06-27
Last updated 2018-06-27
Consultation start date 2018-06-27
Consultation end date 2018-09-30
Email address for submissions PKWPsecretariat@ema.europa.eu